A Randomised Dose De-Escalation Study of Oral Fludarabine, ±Oral Cyclophosphamide and Intravenous Rituximab As First-Line Therapy of Fit Patients with Chronic Lymphocytic Leukaemia (CLL) Aged ≥65 Years: Final Analysis of Response and ToxicityStephen P. Mulligan, Bryone J. Kuss, Melanie Sulda et al.|Blood|2014Cited by 21
A Randomised Dose De-Escalation Safety Study of Oral Fludarabine, ±Oral Cyclophosphamide and Intravenous Rituximab (OFOCIR) As First-Line Therapy of Fit Patients with Chronic Lymphocytic Leukaemia (CLL) Aged ≥65 Years – End of Recruitment Analysis of Response and Toxicity of the Australasian Leukaemia and Lymphoma Group (ALLG) and CLL Australian Research Consortium (CLLARC) CLL5 StudyStephen P. Mulligan, Bryone J. Kuss, Devinder Gill et al.|Blood|2012Cited by 14
Toxicity Is Not Associated with Age or Comorbidity Score in a Randomised Study of Oral Fludarabine and Cyclophosphamide and IV Rituximab (FCR) As First-Line Therapy of Fit, Elderly Patients with Chronic Lymphocytic Leukemia (CLL)Stephen P. Mulligan, Bryone J. Kuss, Devinder Gill et al.|Blood|2014Cited by 5
Primary analysis of the phase 3 randomized trial of selinexor and lenalidomide versus lenalidomide alone as maintenance therapy post autologous stem cell transplant for patients with newly diagnosed multiple myeloma (ALLG MM23; SEALAND)Matthew J. Rees, Hang Quach, Masa Lasica et al.|Blood|2025Cited by 3
5.25 Safety and Tolerability of Oral Fludarabine, with or without Oral Cyclophosphamide and Intravenous Rituximab Therapy, in Previously Untreated Patients with Chronic Lymphocytic Leukaemia Aged 65 Years or Older: Second Interim Analysis from the Australasian Leukaemia and Lymphoma Group and CLL Australian Research Consortium CLL5 StudyStephen P. Mulligan, Gavin Cull, Devinder Gill et al.|Clinical Lymphoma Myeloma & Leukemia|2011Cited by 2